Short answer: some peptides are FDA-approved — as specific, finished drug products, made by specific manufacturers, for specific indications. The compounds sold as research materials are not FDA-approved, and an approval held by a pharmaceutical product does not transfer to any other product containing a similar molecule.
What “FDA-approved” actually means
FDA does not approve molecules in the abstract. It approves drug products: a defined formulation, strength, route, manufacturer and labeled indication, established through a New Drug Application or Biologics License Application. Approval attaches to that product. A different formulation of the same peptide, made by a different party, with different labeling, is not an approved drug — regardless of chemical similarity.
Peptide drugs that do hold FDA approvals
Peptides are a well-established drug class. Examples of approved peptide or peptide-related drug products include:
- Insulin products — the oldest peptide-hormone drug class.
- Semaglutide, liraglutide and tirzepatide — incretin-based drugs for type 2 diabetes and weight management.
- Teriparatide and abaloparatide — parathyroid-hormone-related drugs for osteoporosis.
- Tesamorelin — a GHRH analog approved for HIV-associated lipodystrophy.
- Bremelanotide — a melanocortin-receptor agonist.
- Afamelanotide — a melanocortin agonist implant for erythropoietic protoporphyria.
The authoritative record is FDA’s own database: search any active ingredient at Drugs@FDA. If a compound does not appear there with an approved application, no product containing it is an approved drug.
What approval does not mean for research compounds
Compounds such as BPC-157, TB-500 or MOTS-c have no approved drug application. Materials containing them that are sold for laboratory research are not drugs cleared for human use, and a research-use-only label does not change that; FDA evaluates intended use from the full context of how a product is described and sold (21 CFR 201.128). The broader legal framework is covered in Are Peptides Legal in the United States?
Frequently asked questions
Is a compounded peptide FDA-approved?
No. Compounded preparations are not FDA-approved products. Compounding under section 503A of the FD&C Act is a separate, conditional pathway with its own bulk-substance requirements.
Does a Certificate of Analysis mean a product is approved?
No. A COA is an analytical document: it reports what a laboratory measured about a specific lot — typically purity and identity. It says nothing about regulatory status. What a COA does and does not establish is covered in our overview of third-party peptide testing.
If a peptide is in clinical trials, is it approved?
No. Investigational status means human studies are authorized under controlled conditions, not that any marketed product is approved.
References
- FDA, Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov
- 21 CFR 201.128, Meaning of intended uses. ecfr.gov
- Federal Food, Drug, and Cosmetic Act, sections 201(g)(1), 503A and 505(a).
This article is general information about the U.S. regulatory framework. It is not legal advice, and nothing here should be read as a claim about any product sold on this site.